Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of Empasiprubart (ARGX-117) in healthy volunteers
NCT04532125Phase 1Completed
- Sponsor
- argenx
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empasiprubart in multifocal motor neuropathy (MMN) (4 arms), sponsored by argenx. Primary endpoint: Number of (Serious) Adverse Events up to 42 weeks. Started Aug 2020; status: completed.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT04532125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532125.